Name: MC-MMD-10
Brand: BOC Sciences
Rating: 5 (1 reviews)

Shipping

Room temperature, or blue ice upon request.

Storage

-20°C

MC-MMD-10 is a novel peptide conjugate used in targeted drug delivery systems, particularly in cancer therapy. It consists of a peptide sequence conjugated to a cytotoxic agent, designed to selectively deliver the therapeutic payload to tumor cells. The structure of MC-MMD-10 enables precise targeting of tumor-specific antigens, making it a promising candidate for use in antibody-drug conjugates (ADCs). This specificity ensures that the cytotoxic agent is released directly into the tumor site, minimizing damage to healthy tissues and reducing systemic toxicity.

One of the key applications of MC-MMD-10 is in the development of advanced ADC therapies for cancer treatment. By conjugating a potent cytotoxic payload to a peptide that selectively binds to tumor-specific receptors, MC-MMD-10 enhances the targeted delivery of the drug. This approach increases the concentration of the drug at the tumor site while decreasing its presence in normal tissues, leading to improved treatment efficacy and reduced side effects. MC-MMD-10 is particularly beneficial for cancers with limited treatment options or those that are resistant to conventional therapies.

MC-MMD-10 also plays a crucial role in enhancing the precision of drug delivery systems. Its peptide component is engineered to bind with high affinity to overexpressed tumor markers, ensuring that the cytotoxic drug is released primarily at the site of the tumor. This targeted approach enables higher therapeutic concentrations of the drug at the tumor site, which can improve the overall response to treatment. Additionally, MC-MMD-10 is being investigated for its ability to overcome drug resistance, a common challenge in cancer treatment, by ensuring more efficient and localized drug delivery.

Another significant application of MC-MMD-10 is in research for the optimization of peptide-based drug delivery platforms. Researchers are exploring its potential in various preclinical and clinical studies to improve the pharmacokinetics of cytotoxic drugs. By using MC-MMD-10 in experimental models, scientists aim to refine the design of ADCs, making them more efficient in targeting specific tumors and reducing off-target effects. This research is vital for the development of future personalized cancer therapies, where treatment can be tailored to the unique molecular characteristics of an individual’s tumor.